Clinical characteristics of the FIMM AML patient cohort
| . | . | Total (N = 180) . | Patients with -7/-7q (n = 18; 10%) . | Patients without -7/-7q (n = 162; 90%) . | P value . |
|---|---|---|---|---|---|
| Median age (range), y | 6 (3.3%) NA | 63 (19-81) | 62.5 (22-76) | 63 (19-81) | NS (.66) |
| AML type | De novo, n (%) | 125 (69.4%) | 8 (44.4%) | 117 (72.2%) | .03 |
| sAML/tAML, n (%) | 55 (30.6%) | 10 (55.6%) | 45 (27.8%) | ||
| Disease stage | Diagnosis, n (%) | 115 (63.9%) | 10 (55.6%) | 105 (64.8%) | NS (.08) |
| Relapse, n (%) | 45 (25.0%) | 3 (16.7%) | 42 (25.9%) | ||
| Refractory, n (%) | 20 (11.1%) | 5 (27.8%) | 15 (9.3%) | ||
| Blast percentage (range) | 6 (3.3%) NA | 52.5 (3-95) | 65 (14-92) | 51 (3-95) | NS (.33) |
| FAB | AML M0, n (%) | 8 (4.4%) | 1 (5.6%) | 7 (4.3%) | NS (.19) |
| AML M1, n (%) | 25 (13.9%) | 1 (5.6%) | 24 (14.8%) | ||
| AML M2, n (%) | 42 (23.3%) | 2 (11.1%) | 40 (24.7%) | ||
| AML M4, n (%) | 14 (7.8%) | 1 (5.6%) | 13 (8.0%) | ||
| AML M5, n (%) | 25 (13.9%) | 1 (5.6%) | 24 (14.8%) | ||
| AML M6, n (%) | 1 (0.6) | 0 (0.0%) | 1 (0.6%) | ||
| NA, n (%) | 65 (36.1%) | 12 (66.7%) | 53 (32.7%) |
| . | . | Total (N = 180) . | Patients with -7/-7q (n = 18; 10%) . | Patients without -7/-7q (n = 162; 90%) . | P value . |
|---|---|---|---|---|---|
| Median age (range), y | 6 (3.3%) NA | 63 (19-81) | 62.5 (22-76) | 63 (19-81) | NS (.66) |
| AML type | De novo, n (%) | 125 (69.4%) | 8 (44.4%) | 117 (72.2%) | .03 |
| sAML/tAML, n (%) | 55 (30.6%) | 10 (55.6%) | 45 (27.8%) | ||
| Disease stage | Diagnosis, n (%) | 115 (63.9%) | 10 (55.6%) | 105 (64.8%) | NS (.08) |
| Relapse, n (%) | 45 (25.0%) | 3 (16.7%) | 42 (25.9%) | ||
| Refractory, n (%) | 20 (11.1%) | 5 (27.8%) | 15 (9.3%) | ||
| Blast percentage (range) | 6 (3.3%) NA | 52.5 (3-95) | 65 (14-92) | 51 (3-95) | NS (.33) |
| FAB | AML M0, n (%) | 8 (4.4%) | 1 (5.6%) | 7 (4.3%) | NS (.19) |
| AML M1, n (%) | 25 (13.9%) | 1 (5.6%) | 24 (14.8%) | ||
| AML M2, n (%) | 42 (23.3%) | 2 (11.1%) | 40 (24.7%) | ||
| AML M4, n (%) | 14 (7.8%) | 1 (5.6%) | 13 (8.0%) | ||
| AML M5, n (%) | 25 (13.9%) | 1 (5.6%) | 24 (14.8%) | ||
| AML M6, n (%) | 1 (0.6) | 0 (0.0%) | 1 (0.6%) | ||
| NA, n (%) | 65 (36.1%) | 12 (66.7%) | 53 (32.7%) |
FAB, French-American-British classification; NA, data not available; NS, not significant; sAML, secondary AML; tAML, therapy-related AML.